Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability

Rosamond, 2007, Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 115, e69, 10.1161/CIRCULATIONAHA.106.179918 Liapis, 2009, Fernandes e Fernandes J, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques, Eur J Vasc Endovasc Surg, 37, 1, 10.1016/j.ejvs.2008.11.006 Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, 352, 1685, 10.1056/NEJMra043430 Libby, 2012, Inflammation in atherosclerosis, Arterioscler Thromb Vasc Biol, 32, 2045, 10.1161/ATVBAHA.108.179705 Khokha, 2013, Metalloproteinases and their natural inhibitors in inflammation and immunity, Nat Rev Immunol, 13, 649, 10.1038/nri3499 Higashikata, 2006, Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method, Atherosclerosis, 185, 165, 10.1016/j.atherosclerosis.2005.05.039 Müller, 2014, Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules, Int J Cardiol, 10.1016/j.ijcard.2014.04.071 Rudd, 2002, Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography, Circulation, 105, 2708, 10.1161/01.CIR.0000020548.60110.76 Davies, 2005, Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging, Stroke, 36, 2642, 10.1161/01.STR.0000190896.67743.b1 Tahara, 2014, 2-deoxy-2-[F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis, Nat Med, 10.1038/nm.3437 Ayala-Lopez, 2010, Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages, J Nucl Med, 51, 768, 10.2967/jnumed.109.071324 Winkel, 2013, Folate receptor-targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: Can It distinguish vulnerable from stable atherosclerotic plaques?, Mol Imaging, 12, 1 Müller, 2014, Imaging atherosclerotic plaque inflammation via folate receptor targeting using a novel 18F-folate radiotracer, Mol Imaging, 13, 1, 10.2310/7290.2013.00074 Fujimoto, 2008, Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy, J Am Coll Cardiol, 52, 1847, 10.1016/j.jacc.2008.08.048 Hermann, 2012, Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability?, J Nucl Cardiol, 19, 609, 10.1007/s12350-012-9553-6 Sadeghi, 2010, Imaging atherosclerosis and vulnerable plaque, J Nucl Med, 51, 51S, 10.2967/jnumed.109.068163 Schäfers, 2010, Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques, J Nucl Med, 51, 663, 10.2967/jnumed.109.065698 Newby, 2006, Do metalloproteinases destabilize vulnerable atherosclerotic plaques?, Curr Opin Lipidol, 17, 556, 10.1097/01.mol.0000245262.48258.b4 Galis, 1994, Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques, J Clin Invest, 94, 2493, 10.1172/JCI117619 Pepper, 2001, Extracellular proteolysis and angiogenesis, Thromb Haemost, 86, 346, 10.1055/s-0037-1616232 Visse, 2003, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry, Circ Res, 92, 827, 10.1161/01.RES.0000070112.80711.3D Malemud, 2006, Matrix metalloproteinases (MMPs) in health and disease: an overview, Front Biosci, 11, 1696, 10.2741/1915 Sluijter, 2006, Stroke, 37, 235, 10.1161/01.STR.0000196986.50059.e0 Hobeika, 2007, Matrix metalloproteinases in peripheral vascular disease, J Vasc Surg, 45, 849, 10.1016/j.jvs.2006.09.066 Hugenberg, 2012, A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation, J Med Chem, 55, 4714, 10.1021/jm300199g Schrigten, 2012, A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography, J Med Chem, 55, 223, 10.1021/jm201142w Selivanova, 2013, Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9, J Med Chem, 56, 4912, 10.1021/jm400156p Wagner, 2011, The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbuta namide: Improved precursor synthesis and fully automated radiosynthesis, Appl Radiat Isot, 69, 862, 10.1016/j.apradiso.2011.02.038 Benjamin, 2012, Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease, EXS, 103, 209 Scherer, 2008, Imaging matrix metalloproteinases in cancer, Cancer Metastasis Rev, 27, 679, 10.1007/s10555-008-9152-9 Wada, 2002, Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors, J Med Chem, 45, 219, 10.1021/jm0103920 Nett, 2000, A 20-year follow-up of internal carotid artery endarterectomy with bifurcation advancement, Thorac Cardiovasc Surg, 48, 279, 10.1055/s-2000-7880 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt Method, Methods, 25, 402, 10.1006/meth.2001.1262 Stary, 1995, A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis, Circulation, 92, 1355, 10.1161/01.CIR.92.5.1355 Müller, 2014, Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules, Int J Cardiol, 10.1016/j.ijcard.2014.04.071 Sternlicht, 2001, How matrix metalloproteinases regulate cell behavior, Annu Rev Cell Dev Biol, 17, 463, 10.1146/annurev.cellbio.17.1.463 Gonzalez-Avila, 1998, 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells, Pathobiology, 66, 5, 10.1159/000027989 Sands, 2012, Localization of matrix metalloproteinase (MMP)-9 in lung tissue of a murine model of allergic asthma, Immunol Invest, 41, 87, 10.3109/08820139.2011.584600 Lee, 1996, Purification and characterization of human 92-kDa type IV collagenase (gelatinase B), Exp Mol Med, 28, 161, 10.1038/emm.1996.25 Sukhova, 1999, Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques, Circulation, 99, 2503, 10.1161/01.CIR.99.19.2503 Molloy, 2004, Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity, Circulation, 110, 337, 10.1161/01.CIR.0000135588.65188.14 Laxton, 2009, A role of matrix metalloproteinase-8 in atherosclerosis, Circ Res, 105, 921, 10.1161/CIRCRESAHA.109.200279 Luttun, 2004, Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth, Circulation, 109, 1408, 10.1161/01.CIR.0000121728.14930.DE Schneider, 2008, Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques, Circulation, 117, 931, 10.1161/CIRCULATIONAHA.107.707448 Vihinen, 2005, Matrix metalloproteinases as therapeutic targets in cancer, Curr Cancer Drug Targets, 5, 203, 10.2174/1568009053765799 Newby, 2005, Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture, Physiol Rev, 85, 1, 10.1152/physrev.00048.2003 Fedak, 2003, Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3, Am J Physiol Heart Circ Physiol, 284, H626, 10.1152/ajpheart.00684.2002 Wang, 2011, N-substituted homopiperazine barbiturates as gelatinase inhibitors, Bioorg Med Chem, 19, 4985, 10.1016/j.bmc.2011.06.055